Novel Off-label Use of Desipramine in Infantile Neuroaxonal Dystrophy: Targeting the Sphingolipid Metabolism Pathway to Reduce Accumulation of Ceramide.

This is a research study to find out if clinically prescribed desipramine is effective at improving the symptoms and slowing the progression of Infantile Neuroaxonal Dystrophy (INAD) in affected children.
Participants will receive an initial oral dose of study drug once a day. This dose may be changed depending on response to study drug Clinically collected data will be recorded for up to 5 years. Investigators will also ask for participant permission to obtain a sample of child's skin biopsy from unused clinical sample previously collected for standard of care.

开始日期2019-01-14

申办/合作机构

Duke University

NCT03548454 / Recruiting临床4期IIT

Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization

Over 100 million Americans suffer from chronic pain resulting in annual cost of roughly $635 billion. Limited treatments are available for this widespread disease. The data supporting these treatments lack generalizability to patients with more serious medical and psychological comorbidities who are often excluded from explanatory efficacy trials. Our work aims to integrate randomized comparative effectiveness research with patient care. The investigators will randomize the patients and collect data using an open-source learning healthcare system already in use in our department to monitor patients' progress: Collaborative Health Outcomes Information Registry (CHOIR). Collaborative Health Outcomes Information Registry uses the National Institute of Health Patient Reported Outcomes Measurement Information System item banks for comparative metrics through computer adaptive testing. The investigators will leverage the advantage of this novel system to compare effectiveness of duloxetine and desipramine in decreasing pain in patients with chronic pain. The investigators will also compare adherence of patients to these two commonly used medications over a period of six months. This will evaluate feasibility of integrating randomized comparative effectiveness research with patient care in subspecialty clinics. Collaborative Health Outcomes Information Registry can then be applied for numerous future trials to advance our knowledge in perioperative and pain medicine.

开始日期2018-09-20

申办/合作机构

Stanford University

IRCT20160813029315N2 / Completed临床2/3期IIT

Placebo-controlled randomized clinical trial testing the efficacy of desipramine in reducing craving in patients with methamphetamine use disorder

开始日期2016-06-03

申办/合作机构-

100 项与盐酸地昔帕明相关的临床结果

登录后查看更多信息

100 项与盐酸地昔帕明相关的转化医学

登录后查看更多信息

100 项与盐酸地昔帕明相关的专利（医药）

登录后查看更多信息

7,322

项与盐酸地昔帕明相关的文献（医药）

2024-02-22·Environmental science and pollution research international

Preparation of a novel polypyrrole/dolomite composite adsorbent for efficient removal of Cr(VI) from aqueous solution.

Article

作者: Ling Xiong ; Fen Zhang ; Yanan Yang ; Yuqing Ding ; Shaohua Chen

A novel adsorbent, deposited PPy on the DMI (PPy/DMI) composite, was successfully synthesized for Cr(VI) removal from aqueous solution. PPy/DMI composite was characterized by BET, SEM, TEM, XRD, and XPS. The SEM and TEM analyses revealed that DMI can greatly reduce the aggregation of PPy and significantly enhance its adsorption performance. The Cr(VI) removal was highly pH dependent. The high selectivity of PPy/DMI composite for Cr(VI) removal was found even in the presence of co-existing ions. The adsorption kinetic process followed the pseudo-second-order equation, demonstrating that the Cr(VI) adsorption behavior onto PPy/DMI is chemisorption. Furthermore, the intra-particle diffusion model implied that the adsorption was controlled by both liquid membrane diffusion and internal diffusion. The adsorption isotherm data fitted well with the Langmuir model with the maximum adsorption capacity (406.50 mg/g at 323 K) which was considerably higher than that of other PPy-based adsorbents. The Cr(VI) adsorption onto PPy/DMI composite was endothermic. The main mechanisms of Cr(VI) removal are involved in adsorption through electrostatic attractions, ion exchange, and in situ reduction. The results suggested that PPy/DMI composite could be a promising candidate for efficient Cr(VI) removal from aqueous solution.

2024-02-21·Journal of dairy science

Effects of feeding rumen-protected lysine during the postpartum period on performance and amino acids profile in dairy cows: A meta-analysis.

Article

作者: U Arshad ; F Peñagaricano ; H M White

Lysine is one of the limiting AA in the diets of dairy cows and is typically fed as rumen-protected Lys (RPL). We hypothesized that supplementation of RPL during the postpartum period would improve the productive performance in dairy cows. Objectives were to use meta-analytic methods to explore the effects of feeding RPL on performance and blood AA profile in lactating dairy cows. An additional objective was to identify an optimal concentration (%) of Lys in metabolizable protein (LYSMP) and determine if responses to LYSMP were associated with the concentration (%) of Met in metabolizable protein (METMP). The literature was systematically reviewed and 13 experiments, comprising 40 treatment means and 594 lactating cows, were included in the meta-analysis. All experiments had a non-supplemental control (CON; n = 17 treatment means), or a supplemental group (RPL; n = 23 treatment means). Cows supplemented with RPL were supplied additionally with a mean (±standard deviation) 19.3 ± 10.3 g/d metabolizable Lys (5.1 to 40.6 g/d). Meta-analytical statistics were used to estimate the weighted mean difference in STATA. Mixed models were fitted to the data to investigate the linear and quadratic effects of LYSMP, METMP, and interactions between LYSMP and METMP. All models included the random effect of experiment and weighting by the inverse of the standard errors of the means squared. Cows that began receiving RPL in early lactation (≤90 d in milk) or for an extended duration (≥70 d in milk) produced 1.51 kg/d more milk compared with CON cows. Increasing digestible LYSMP from 6.5 to 8.5% linearly increased yields of milk, fat-corrected milk (FCM), energy-corrected milk (ECM), and milk fat by 1.8, 2.5, 2.4, and 0.10 kg/d, respectively, and tended to increase milk protein yield and body weight gain by 0.07 and 0.09 kg/d, respectively, without a concurrent increase in dry matter intake (DMI). Interactions between linear effect of LYSMP and METMP were observed for FCM/DMI or ECM/DMI. In a diet with low METMP (e.g., 1.82% of MP), a digestible supply of 7.40% LYSMP would result in 1.46 and 1.47 kg/kg FCM/DMI or ECM/DMI, respectively; however, with high digestible METMP (e.g., 2.91% of MP), supplying 7.40% of digestible LYSMP would result in 1.68 and 1.62 kg/kg FCM/DMI or ECM/DMI, respectively. Increasing digestible LYSMP from 6.5 to 8.5% linearly increased blood concentrations of Lys by 16.6 µM, whereas blood concentrations of Met and Ala decreased by 4.6 and 6.0 µM, respectively. Nevertheless, an interaction was also observed between LYSMP and METMP for blood concentrations of total EAA because as METMP increased, the positive response to LYSMP on total EAA was also increased, suggesting a competitive mobilization of AA and their utilization in various body tissues. Only 4 out of the 13 experiments in this meta-analysis involved primiparous cows, thus, there was insufficient data to understand the role of supplemental RPL in primiparous cows. Collectively, feeding RPL improved productive performance and the increments were maximized up to 9.25% of LYSMP in multiparous dairy cows.

2024-02-16·Transplantation

Pharmacomicrobiomics: Immunosuppressive Drugs and Microbiome Interactions in Transplantation.

Article

作者: Moataz E Mohamed ; Abdelrahman Saqr ; Christopher Staley ; Guillaume Onyeaghala ; Levi Teigen ; Casey R Dorr ; Rory P Remmel ; Weihua Guan ; William S Oetting ; Arthur J Matas ; Ajay K Israni ; Pamala A Jacobson

The human microbiome is associated with human health and disease. Exogenous compounds, including pharmaceutical products, are also known to be affected by the microbiome, and this discovery has led to the field of pharmacomicobiomics. The microbiome can also alter drug pharmacokinetics and pharmacodynamics, possibly resulting in side effects, toxicities, and unanticipated disease response. Microbiome-mediated effects are referred to as drug-microbiome interactions (DMI). Rapid advances in the field of pharmacomicrobiomics have been driven by the availability of efficient bacterial genome sequencing methods and new computational and bioinformatics tools. The success of fecal microbiota transplantation for recurrent Clostridioides difficile has fueled enthusiasm and research in the field. This review focuses on the pharmacomicrobiome in transplantation. Alterations in the microbiome in transplant recipients are well documented, largely because of prophylactic antibiotic use, and the potential for DMI is high. There is evidence that the gut microbiome may alter the pharmacokinetic disposition of tacrolimus and result in microbiome-specific tacrolimus metabolites. The gut microbiome also impacts the enterohepatic recirculation of mycophenolate, resulting in substantial changes in pharmacokinetic disposition and systemic exposure. The mechanisms of these DMI and the specific bacteria or communities of bacteria are under investigation. There are little or no human DMI data for cyclosporine A, corticosteroids, and sirolimus. The available evidence in transplantation is limited and driven by small studies of heterogeneous designs. Larger clinical studies are needed, but the potential for future clinical application of the pharmacomicrobiome in avoiding poor outcomes is high.

项与盐酸地昔帕明相关的新闻（医药）

2023-11-28

·药研网

探寻抑郁症新型可行性靶点

2023年8月，Sage治疗产后抑郁的药物Zurzuvae获FDA批准上市，成为FDA批准的首款专门用于产后抑郁的口服药；继而2023年9月，Fabre-Kramer治疗重度抑郁的药物Exxua获FDA批准上市，历时20年，被FDA拒绝三次，终于在第四次申请时获批上市。重度抑郁症是全世界非常普遍的疾病之一，且抑郁症的发展越来越趋于年轻化，青少年患抑郁症的比例不断升高。青少年患重度抑郁更为棘手，因为其将面临一生的负面影响。据《2022年国民抑郁症蓝皮书》显示，国内50%的抑郁症患者为在校学生，18岁以下的抑郁症患者占总人数的30%。有研究认为，成年期抑郁症在青少年时期已发病。目前青少年治疗抑郁的首选药物是氟西汀，但也有一些显著的副作用，如增加自杀意念。而成年的抗抑郁药以选择性5-HT再摄取抑制剂（SSRIs）为主，包括氟西汀、帕罗西汀、舍曲林、氟伏沙明、西酞普兰、艾司西酞普兰，但大约 35-50% 的患者对这些药物没有反应，且通常具有嗜睡、镇静和性功能障碍等常见不良反应。近几年，也有一些新机制抗抑郁药获批，如NMDA受体拮抗剂Spravato，GABAA受体正向变构调节剂Zulresso。但其仅获批用于部分适应症，如Spravato 仅适用于耐药性抑郁症，Zulresso仅用于产后抑郁症。因此，需要寻找更安全，新机制的药物靶点，开发疗效更佳的新型抗抑郁药物。神经可塑性作为抗抑郁机制在重度抑郁患者中，前额叶皮层（PFC）和海马体体积缩小是大脑解剖学上的一致发现，前额叶皮层的突触数量也有所减少。这一事实表明，神经可塑性是 MDD 生理病理学中一个基本而关键的现象。动物和临床研究表明，慢性压力是 MDD 的病因，它会导致 PFC 和海马突触的数量和功能下降。SSRIs 可增加抑郁症患者血清和大鼠海马中脑源性神经营养因子（BDNF）的表达，而 BDNF 是新突触形成所必需的。只有在对大鼠长期（两周以上）而非急性服用 SSRIs 后，BDNF 才会增加，这表明 BDNF 以及神经可塑性参与了在行为中观察到的抗抑郁效果。Specific targets related to the modulation of synaptic plasticity and energetic metabolism. 以新兴神经递质系统为目标除了血清素和谷氨酸外，GABAergic和cholinergic两种神经递质系统也被认为是治疗 MDD 的有效药物。磁共振波谱（MRS）研究证实，抑郁症患者脑脊液（CSF）中的 GABA 含量降低。在有效治疗 MDD 后，GABA 水平也会恢复正常。动物研究显示，慢性压力会诱导啮齿动物GABA合成酶的表达以及 GABA 的释放和摄取减少。此外，GABAA 表达减少的小鼠会出现类似抑郁症的表型，长期服用地西帕明可以改善这种情况。在使用cholinergic拮抗剂 scopolamine进行临床前研究期间，观察到了抗抑郁效果，在动物模型中也观察到了scopolamine的突触生成和激活mTOR信号转导的作用，这些效应暗示了乙酰胆碱在多发性抑郁症中的作用。但也有研究显示安慰剂组和scopolamine组在抗抑郁方面无显著差异。因此目前关于cholinergic系统作为抗抑郁靶点的潜力，目前尚无定论。褪黑素在使用 5-10 mg褪黑素的随机研究中，与安慰剂相比，双相情感障碍和单相情感障碍患者在服用褪黑素后都没有观察到显著的抗抑郁效果。同时，Fava 等人在一项双盲研究中表明，丁螺环酮与 3mg褪黑素联合使用比丁螺环酮与安慰剂联合使用更有效。Lewy等人的研究表明，当根据时间型调整给药剂量时，褪黑激素对季节性情感障碍的抗抑郁作用更大从目前的研究来看，褪黑素可能成为抗抑郁治疗的有效辅助药物，而非主要治疗手段。神经炎症：色氨酸-犬尿氨酸途径神经炎症与多种神经系统疾病有关，炎症和细胞介导的免疫激活是抑郁症的关键因素。动物模型显示，暴露于脂多糖可诱发抑郁样行为。此外，人体研究和荟萃分析表明，抑郁症患者血液和脑脊液中的外周促炎标志物水平升高。与此相对应，耐药性 MDD 患者的促炎细胞因子继续增加。这证实了促炎细胞因子水平与抑郁症严重程度之间的正相关性。The tryptophan – kynurenic acid metabolic pathway and major depressive disorder. 对用于治疗 MDD 的抗炎药物进行的 Meta 分析表明，非甾体类抗炎药物（NSAIDs）的单一疗法或作为辅助疗法的使用可改善抑郁症状，且缓解率较高。然而，尽管大多数非甾体抗炎药抑制环氧化酶（COX），但人们对其在抑郁症中的作用持怀疑态度。能量代谢、线粒体2 型糖尿病（DM）、肥胖症和肌肉疏松症等几种新陈代谢疾病与抑郁症发病几率增加有关。鉴于新陈代谢紊乱、氧化应激和神经炎症与抑郁症的关系，对作用于新陈代谢的药物进行了测试，结果发现这些药物具有抗抑郁作用。据报道，对于患有心脏代谢紊乱的患者，抗糖尿病药物可减轻抑郁症状。线粒体功能障碍是代谢性疾病的典型症状。多发性抑郁症患者的线粒体活性以及一系列线粒体蛋白的表达都会下降，他们的神经元代谢也会出现缺陷。抗抑郁治疗可改善这种代谢缺陷。线粒体基因突变也与抑郁症有关。因此，新陈代谢和线粒体功能可能是改变 MDD 病理生理学的重要部位。与线粒体功能相关的三个潜在靶点包括Complex I、NAD 和 CoQ 10。与代谢相关的潜在靶点包括二甲双弧，GLP-1。The gut–brain axis as a target微生物组近年来，由于人们对肠道微生物群如何影响大脑功能的认识上取得了最新进展，"肠脑轴"在生物医学研究中备受关注。研究表明，多发性抑郁症患者的肠道微生物组发生了改变，细菌多样性减少。在小鼠体内，一些细菌及其代谢产物能够增加抑郁样行为的易感性，并阻碍某些药物的抗抑郁效果。相反，其他代谢物则能改善小鼠的认知能力和情绪。一项动物研究表明，将 MDD 患者的粪便移植到非生物小鼠体内会导致抑郁症状的出现，如失乐症和焦虑样行为，以及 TRY 代谢的改变。一项临床研究表明，有八种不同细菌菌株的益生菌混合物具有抗抑郁作用，而乳酸菌数量的增加推动了这种作用。但尽管调整肠道微生物组具有成本效益和实用性等优势，但由于组成肠道微生物组的微生物物种数量庞大，确定哪些细菌群可能影响行为改变具有挑战性。此外，还需要确定微生物组影响大脑的机制，以便更准确地了解潜在的目标。肠道微生物组及其代谢物可被视为开发抗抑郁药物的良好候选物，但还需要进一步的临床证据。细胞系产品查询投稿丨商务合作转载丨加交流群往期推荐恒瑞医药生物药管线全梳理中生制药企业梳理石药集团生物药技术平台及管线梳理国内ADC热门靶点竞争格局一览点击下方“药研网”，关注更多精彩内容

上市批准临床研究

2023-11-22

·PRNewswire

Novel MRI Reveals Brain Changes in Long-COVID Patients

CHICAGO, Nov. 22, 2023 /PRNewswire/ -- People with long COVID exhibit patterns of changes in the brain that are different from fully recovered COVID-19 patients, according to research being presented next week at the annual meeting of the Radiological Society of North America (RSNA). "To the best of our knowledge, this is the first study comparing patients with long COVID to both a group without history of COVID-19 and a group that went through a COVID-19 infection but is subjectively unimpaired," said one of the study's lead authors, Alexander Rau, M.D., resident in the Departments of Neuroradiology and Diagnostic and Interventional Radiology at University Hospital Freiburg in Freiburg, Germany. After infection with COVID-19, as many as 10-25% of patients may develop a post-COVID condition commonly referred to as "long COVID." People with long COVID may experience a wide variety of symptoms, including difficulty concentrating ("brain fog"), change in sense of smell or taste, fatigue, joint or muscle pain, shortness of breath, digestive symptoms, and more. These symptoms may persist for weeks, months, or—as is only now becoming apparent—years after COVID-19 infection. However, the basis of this condition is poorly understood. Diffusion microstructure imaging (DMI), a novel MRI technique, is a promising approach to fill this gap. DMI looks at the movement of water molecules in tissues. By studying how water molecules move in different directions and at various speeds, DMI can provide detailed information on the microstructure of the brain. It can detect even very small changes in the brain, not detectable with conventional MRI. For this prospective, cross-sectional study, Dr. Rau and colleagues compared MRI brain scans of three groups: 89 patients with long COVID, 38 patients that had contracted COVID-19 but did not report any subjective long-term symptoms, and 46 healthy controls with no history of COVID-19. The researchers first compared the cerebral macrostructure of these three groups to test for atrophy or any other abnormalities. Next, they used DMI to gain a deeper insight into the brain. The three groups were compared to reveal group differences in the brain's microstructure. DMI parameters were read for the gray matter in the brain. Additionally, whole brain analyses were employed to reveal the spatial distribution of alterations and associations with clinical data, including long-COVID symptoms like fatigue, cognitive impairment or impaired sense of smell. The results showed no brain volume loss or any other lesions that might explain the symptoms of long COVID. However, COVID-19 infection induced a specific pattern of microstructural changes in various brain regions, and this pattern differed between those who had long COVID and those who did not. "This study allows for an in vivo insight on the impact of COVID-19 on the brain," Dr. Rau said. "Here, we noted gray matter alterations in both patients with long-COVID and those unimpaired after a COVID-19 infection. Interestingly, we not only noted widespread microstructural alterations in patients with long COVID, but also in those unimpaired after having contracted COVID-19." The findings also revealed a correlation between microstructural changes and symptom-specific brain networks associated with impaired cognition, sense of smell and fatigue. "Expression of post-COVID symptoms was associated with specific affected cerebral networks, suggesting a pathophysiological basis of this syndrome" Dr. Rau said. The researchers hope to reexamine the patients in the future, recording both clinical symptoms and changes to the brain's microstructure. Despite these brain imaging findings, it remains unclear why some people develop long COVID while others do not, although previous studies have identified risk factors including female sex, older age, higher body mass index, smoking, preexisting comorbidities, and previous hospitalization or intensive care unit admission. Co-authors are Jonas A. Hosp, M.D., Nils Schroter, M.D., Marco Reisert, Ph.D., Horst Urbach, M.D., Cornelius Weiller, M.D., and Elias Kellner, Ph.D. Note: Copies of RSNA 2023 news releases and electronic images will be available online at RSNA.org/press23. RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org) Editor's note: The data in these releases may differ from those in the published abstract and those actually presented at the meeting, as researchers continue to update their data right up until the meeting. To ensure you are using the most up-to-date information, please call the RSNA Newsroom at 1-312-791-6610. For patient-friendly information on brain MRI, visit RadiologyInfo.org. SOURCE Radiological Society of North America (RSNA)

临床结果

2023-07-09

·药融圈

盘点FDA批准上市抗抑郁药物

▲8月03-04日 CMC-China大会 · 限时免费扫码报名中注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。全球范围内抑郁症的发病率在不断增长，抑郁症已经成为全球最常见的心理健康问题之一。据世界卫生组织(WHO)统计，全球约10亿人正在遭受精神障碍困扰，每40秒就有一人因自杀而失去生命，低收入和中等收入国家的自杀人数占全球自杀人数的77%。2019年黄悦勤教授团队发表在《柳叶刀·精神病学》的研究首次报告了我国的抑郁症患者中，女性约占65%，67%的抑郁症患者超过35岁。随着社会的进步以及人们对抑郁症的重视，越来越多的抗抑郁药物批准上市，通过非药物疗法(精神或心理)、药物治疗，多数患者能获得一定程度的恢复与改善。更多医药企业布局抑郁症市场，力图以科学的力量能帮助所有受抑郁折磨的人们。抑郁症确切的病理机制尚不清楚，按发病原因可将抑郁分为原发性和继发性。目前常见的对中度和重度抑郁症治疗的药物，包含以下几种：01选择性5-羟色胺再摄取抑制剂（SSRIs）代表药：氟西汀(Fluoxetine)、氟伏沙明(Fluvoxamine)、帕罗西汀(Paroxetine)、舍曲林(Sertraline)、西酞普兰(Citalopram)及艾司西酞普兰(Escitalopram)SSRIs选择性地抑制5-HT回收，间接提升突触间隙5-HT的浓度。对5-HT有高度选择性、对NE、DA、组胺及胆碱能神经影响较小。由于其不良反应轻而少，易于耐受，安全性高，快速钠通道无抑制作用，即使过量亦无生命危险，服用方便，适用于各种类型抑郁症，在世界各国均被作为抗抑郁药的首选。025-羟色胺和去甲肾上腺素再摄取抑制剂（SNRIs）代表药：瑞波西汀(Reboxetine)、维洛沙嗪(Viloxazine)和阿托西汀(Atomoxetine)选择性NA再摄取抑制剂(SNRIs)药物比SSRIs药物出现的晚。瑞波西汀作为第一个该类上市药物在上世纪90年代在欧洲上市。该类药物选择性抑制NA再摄取，对5-HT和DA的影响小，对MAO-A无抑制作用，对α-肾上腺素受体、毒蕈碱样胆碱能受体的亲和力极低。其中瑞波西汀对用其他抗抑郁药治疗无效的重症抑郁患者疗效较好，而且瑞波西汀可被作为5-HT能药物治疗困难病例时的辅助药物。03三环类（TCAs）代表药：米帕明(Imipramine)、地昔帕明(Desipramine)、氯米帕明(Clomipramine)、多塞平(Doxepin)和普罗替林(Protriptyline)等三环类抗抑郁药的确切作用机制尚不清楚，一般认为它可影响脑内5-HT和NA含量的平衡，即抑制突触间隙中5-HT和NA的再摄取，以增加突触间隙中单胺递质的浓度。这类药物的化学结构与精神分裂症药物相似(如氯米帕明)，除了对5-HT和NA具有再摄取作用外，三环类药物还同时拮抗突触后α1-肾上腺素受体、组胺(H1)受体和5-HT2受体等。TCAs不仅广泛用于抑郁症的治疗，对惊恐发作、强迫状态、贪食症、儿童多动症及遗尿症等也有一定疗效。04单胺氧化酶抑制剂（MAOIs）代表药：吗氯贝胺（moclobemide）适于各类抑郁症，常见头痛、头晕、口干、便秘及失眠等不良反应。不宜与其他类抗抑郁药合用。05去甲肾上腺素和特异性5-羟色胺能抗抑郁药（NaSSAs）代表药：米氮平（Mirtazapine）适于各类抑郁症的急性期及维持期，常见不良反应为体重增加。065-羟色胺受体拮抗和再摄取抑制剂（SARIs）代表药：曲唑酮（Trazodone）适于轻、中度抑郁症。常见胃肠道反应、镇静、头晕等不良反应。禁用于低血压，室性心律失常。目前常见的抗抑郁一线用药通常以SSRIs、SNRIs及NaSSAs为主。版权声明：本文转自药事纵横，如不希望被转载的媒体或个人可与我们联系，我们将立即删除关于CMC-China 博览会融合产业力量，重构行业未来！本次CMC-China博览会汇聚300+医药及上下游全产业链的企业积极报名参展，数千名专业观众报名参观，展会现场将举办15场专业论坛。充分体现了“医药人办医药展，专业人办专业展”的理念。了解更多：数据看展会丨一文看懂第五届CMC-China制药博览会观众亮点点分享点点赞点在看

上市批准医药出海

100 项与盐酸地昔帕明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00812	盐酸地昔帕明	N06AA01	DB01151

研发状态

适应症	最高研发状态	国家/地区	公司
抑郁症	批准上市	美国更多	Validus Pharmaceuticals LLC 更多
-	撤市	加拿大更多	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00990691 (Pubmed \| Ann Clin Transl Neurol)	临床2期	Rett综合征	36	high Desipramine	(繭襯鬱獵廠積構鏇範鬱) = 鏇範鹽衊鏇顧鹹憲襯築淵齋鑰獵餘觸鹽築醖範 (製選糧廠艱鏇積壓獵襯, -37 ~ -11)	不佳	2018-02-01
				low Desipramine	(繭襯鬱獵廠積構鏇範鬱) = 糧繭襯壓襯蓋鹽簾襯簾淵齋鑰獵餘觸鹽築醖範 (製選糧廠艱鏇積壓獵襯, -31 ~ 13)
NCT00000271 (Pubmed \| Drug Alcohol Depend)	临床2期	抑郁症	111	Desipramine	鹹夢鏇鹽鹽願製鑰製鏇(餘襯觸簾構簾網鑰鑰獵) = 鹹齋醖齋齋鬱願構鹹遞鏇鹽獵糧鹽繭繭積鹹鏇 (鏇獵鹽鹹選鑰網蓋廠願 )	-	2005-11-01
				Placebo	鹹夢鏇鹽鹽願製鑰製鏇(餘襯觸簾構簾網鑰鑰獵) = 糧憲鹹繭膚憲遞獵衊製鏇鹽獵糧鹽繭繭積鹹鏇 (鏇獵鹽鹹選鑰網蓋廠願 )
NCT01899326 (CTgov)	N/A	浆细胞骨髓瘤难治	10	Laboratory Biomarker Analysis+Filgrastim+Desipramine Hydrochloride	艱築蓋顧願構製獵觸網(壓製鏇網觸範醖窪獵壓) = 壓憲鑰遞糧壓壓鬱蓋積鬱壓壓簾蓋糧願窪夢鑰 (鹹簾築淵鹹觸觸遞顧夢, 獵範襯獵憲築醖壓繭廠 ~ 範積獵壓觸蓋窪膚糧齋) 更多	-	2023-03-28
NCT03726996 (CTgov)	临床4期	神经轴索营养不良	4	Desipramine	淵餘夢積簾窪遞衊鏇繭(廠醖顧鹹獵獵壓網艱簾) = 鑰壓憲願壓壓鬱築築繭鏇繭網醖糧範簾壓壓範 (窪糧選齋鏇簾蓋醖選獵, 衊淵獵構繭衊膚壓選膚 ~ 獵廠襯製選鑰淵膚鬱鹽) 更多	-	2020-10-14
ERS2015	N/A	肺损伤	-	Desipramine	餘夢顧壓鑰淵壓廠製簾(願選觸選鑰鹽醖遞艱廠) = 齋鑰鬱築憲壓鑰簾鑰壓遞構淵齋窪遞膚衊構窪 (積糧膚膚獵製鹹鏇簾選 )	-	2015-09-01
				LPS	餘夢顧壓鑰淵壓廠製簾(願選觸選鑰鹽醖遞艱廠) = 蓋簾範積廠壓蓋鬱製觸遞構淵齋窪遞膚衊構窪 (積糧膚膚獵製鹹鏇簾選 )
NCT01719861 (CTgov)	临床2期	神经内分泌肿瘤 \| 小细胞肺癌	6	Desipramine HCL	憲鑰製網餘壓網遞蓋膚(膚廠窪製範膚餘夢選鹹) = 艱鏇獵齋鑰網齋遞窪鏇廠鹹窪淵選夢餘鹽製艱 (鹹夢餘簾糧鹹願繭選衊, 遞廠窪鏇蓋選構餘積壓 ~ 選鹽醖糧遞網壓壓蓋構) 更多	-	2017-04-17
NCT01358968 (CTgov)	临床1期	肿瘤	20	Desipramine+Gemcitabine+LY2603618+Pemetrexed	廠壓網餘獵艱獵簾繭築(夢膚膚顧醖鑰製簾網鹽) = 廠繭遞觸憲壓顧獵憲築餘鏇觸鬱衊構醖願膚鬱 (窪糧構艱範夢觸壓鑰網, 鹽壓餘醖夢襯壓選範積 ~ 鑰網鹽餘餘衊繭膚簾蓋) 更多	-	2018-10-25
ISTH2021	N/A	-	-	Desipramine	鏇繭鬱鏇淵淵餘選憲鑰(醖淵遞繭積積餘製夢襯) = 糧獵艱遞襯鏇鬱願醖鹽鑰夢夢繭鬱簾鹹窪顧衊 (壓糧窪餘簾鑰觸醖製觸 )	-	2021-07-17
				PRP pre-incubated with 10μM desipramine	鏇繭鬱鏇淵淵餘選憲鑰(醖淵遞繭積積餘製夢襯) = 廠艱鹽蓋鏇夢膚顧艱構鑰夢夢繭鬱簾鹹窪顧衊 (壓糧窪餘簾鑰觸醖製觸 )
NCT01411085 (CTgov)	临床2期	精神分裂症 \| 酗酒	12	Risperidone+Desipramine	餘壓襯範糧選蓋觸構鬱(觸醖窪憲窪鹹構鬱觸醖) = 鹽選築壓壓範簾鏇遞積壓鑰構廠衊壓齋壓觸壓 (憲鹹願糧襯選醖憲鹽衊, 齋鏇壓遞繭夢網築顧選 ~ 範網艱鹹夢襯糧鑰觸艱) 更多	-	2018-03-23
NCT02428478 (CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征	17	Desipramine (Desipramine)	衊鹽選醖壓鏇壓淵淵廠(簾憲鹽糧繭範艱壓鏇淵): ; 更多	-	2017-03-30
				Placebo+desipramine (Placebo)